| Name | Title | Contact Details |
|---|
We`ve created a global health marketplace where patients are empowered to make the healthcare choices that work for them.
Deep Hospitality Knowledge Mission Hill Hospitality is the KSL Capital portfolio company launched to transform select service and extended stay hotel investing. KSL is a global leader in hospitality, travel, and leisure investing. The Mission Hill team has decades of lodging experience, with a wide range of expertise across functions including operations, asset management, acquisitions, development, and capital markets. Industry Advantage Mission Hill`s approach combines the benefits of KSL`s world-leading, world-class hospitality model, with our seasoned team`s broad relationships with owners, managers, premium brands, and developers, enabling us to create the highest quality asset portfolio. Value Added Mission Hill`s value-add strategy seeks to maximize the performance of each investment while elevating the client experience. By hand-picking assets in preferred markets across the country, we avoid inherent information asymmetry and premiums associated with acquiring a portfolio. Our disciplined approach to underwriting gives us the ability to secure outsized risk adjusted returns.
Hanna Boys Ctr is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Sonoma, CA. To find more information about Hanna Boys Ctr, please visit www.hannacenter.org
Cognition Health Partners is a Panama City Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.